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ARTICLE
A RUNX2 stabilization pathway mediates
physiologic and pathologic bone formation
Jung-Min Kim1, Yeon-Suk Yang1, Kwang Hwan Park2, Xianpeng Ge1, Ren Xu 3, Na Li3, Minkyung Song4,
Hyunho Chun5, Seoyeon Bok6, Julia F. Charles 7, Odile Filhol-Cochet 8, Brigitte Boldyreff9, Teresa Dinter10,
Paul B. Yu 10, Ning Kon11, Wei Gu 11,12, Takeshi Takarada 13, Matthew B. Greenblatt6✉ &
Jae-Hyuck Shim 1,14✉
The osteoblast differentiation capacity of skeletal stem cells (SSCs) must be tightly regulated,
as inadequate bone formation results in low bone mass and skeletal fragility, and over-
exuberant osteogenesis results in heterotopic ossification (HO) of soft tissues. RUNX2 is
essential for tuning this balance, but the mechanisms of posttranslational control of RUNX2
remain to be fully elucidated. Here, we identify that a CK2/HAUSP pathway is a key regulator
of RUNX2 stability, as Casein kinase 2 (CK2) phosphorylates RUNX2, recruiting the deubi-
quitinase herpesvirus-associated ubiquitin-specific protease (HAUSP), which stabilizes
RUNX2 by diverting it away from ubiquitin-dependent proteasomal degradation. This path-
way is important for both the commitment of SSCs to osteoprogenitors and their subsequent
maturation. This CK2/HAUSP/RUNX2 pathway is also necessary for HO, as its inhibition
blocked HO in multiple models. Collectively, active deubiquitination of RUNX2 is required for
bone formation and this CK2/HAUSP deubiquitination pathway offers therapeutic opportu-
nities for disorders of inappropriate mineralization.
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As shown by both disorders of inappropriate bone forma-tion, such as heterotopic ossification (HO) and disordersof deficient bone formation, such as osteoporosis, the
capacity of skeletal stem cells (SSCs) to differentiate into bone-
forming osteoblasts must be tuned in a context and tissue
dependent manner. One of the best established molecular path-
ways regulating osteogenesis is the transcription factor RUNX2,
which is required for both the commitment of skeletal progeni-
tors to osteoprogenitors and the subsequent differentiation of
osteoprogenitors1,2. As a master transcriptional regulator of
skeletogenesis, RUNX2 is expressed in both mouse and human
skeletal progenitors3,4. Mice with germline deletion of Runx2
(Runx2−/−) show a complete absence of mineralized bone in both
calvaria and long bones, suggesting that RUNX2 is required for
both intramembranous and endochondral bone formation5. In
addition, haploinsufficiency for RUNX2 causes cleidocranial
dysplasia (CCD), as characterized by open fontanels, hypoplastic
clavicles, supernumerary teeth, and short stature, in both humans
and mice6,7. On the other hand, excessive osteoblast differentia-
tion can lead to disorders of ectopic mineralization, and RUNX2
is necessary for the pathogenesis of ectopic mineralization as
shown in human HO patients and mouse HO models8–11. Thus,
fine-tuning of RUNX2 expression and transcriptional activity is
crucial for both physiologic and pathologic bone formation.
While there are examples of regulating RUNX2 activity and
stability via phosphorylation12,13, acetylation14, or ubiquitina-
tion15–17, how posttranslational mechanisms control RUNX2 in
initial commitment to the osteoblast lineage and subsequently
sustained to drive osteoblast differentiation remain to be fully
elucidated.
Here we identify a key pathway stabilizing RUNX2 via Casein
Kinase 2 (CK2 encoded by Csnk2)-mediated phosphorylation of
RUNX2 leading to recruitment of the deubiquitinase herpesvirus-
associated ubiquitin-specific protease (HAUSP, also known as
USP7). HAUSP was identified as a regulator of the MDM2 and
p53 pathway18,19. HAUSP also controls a wide array of substrates
involved in immune responses, virus replication and infection,
mitosis, DNA replication, and DNA damage repair18–20. CK2 is a
constitutively active serine/threonine kinase that controls a
multitude of signaling proteins linked to cell cycle progression,
cell growth and differentiation21,22. CK2 is typically composed of
a tetrameric complex including two catalytic α (Csnk2a1)- or α’
(Csnk2a2)-subunits and two regulatory β subunits (Csnk2b)23–25.
The two catalytic subunits have high similarity in the catalytic
domain, although there is tissue-specific functional specialization
during embryonic development and as well as functional com-
pensation dependent on their expression levels26. The C-terminal
regions of the β-subunits bind the α-subunits and enhance the
catalytic activity and stability of CK2 complex. Previous in vitro
studies demonstrated a suppressive role of CK2 in osteoblast
differentiation and bone morphogenetic protein (BMP)
signaling27,28. However, its function in the skeleton has not been
studied. Here, we demonstrate that CK2-induced phosphoryla-
tion of RUNX2 recruits the deubiquitinase HAUSP for the sta-
bilization of RUNX2 and that this pathway is required for
physiologic and pathologic bone formation.
Results
CK2 is required for osteoblast differentiation. HO, abnormal
bone formation in soft tissues, occurs sporadically after burns,
traumatic brain injury, fractures and dislocations, and operative
procedures, resulting in restricted joint mobility, severe pain, and
nerve entrapment29–32. HO is postulated to reflect the aberrant
differentiation of soft tissue-resident stem cells to osteoblasts33.
Our data and others demonstrated elevated mRNA levels of
Runx2, a key regulator of osteogenesis, in mouse HO tissues
(Supplementary Fig. 14a), accompanied with a high expression of
RUNX2 protein in human and mouse HO tissues (Fig. 1a and
Supplementary Figs. 1b, 14c, f). Since RNAi-mediated knock-
down of RUNX2 prevented HO in mice8,9, we aimed to identify
the pathways controlling RUNX2. Previously, a high-throughput
short hairpin RNA (shRNA) screen was performed in human
bone marrow-derived mesenchymal stromal cells (BMSCs) using
an alkaline phosphatase (ALP) assay, a marker of early osteoblast
differentiation in order to identify kinases and/or phosphatases
required for osteoblast differentiation34,35. In this study, shRNAs
that suppress ALP activity in the primary screen were further
examined in human BMSCs expressing a RUNX2-responsive
luciferase reporter gene (OG2-luc) to identify kinases and/or
phosphatases that specifically control RUNX2 activity/stability.
This identified Casein Kinase 2 (CK2, CSNK2) as a putative
regulator of BMSC differentiation into osteoblasts and RUNX2
activation. ALP activity was markedly reduced by knockdown of
CSNK2A2 or CSNK2B, but not CSNK2A1 (Fig. 1b). In particular,
CSNK2B-deficiency showed the strongest effect on ALP activity,
extracellular matrix mineralization, and osteogenic gene expres-
sion (Fig. 1b–d and Supplementary Fig. 2a). Moreover, these
BMSCs showed a significant reduction in transcriptional activity
of RUNX2 (Fig. 1e, f). We next sought to identity the relevance of
these findings in primary human osteogenic progenitors. While
the human SSCs serving as a source of osteoblasts after growth
plate closure are currently unclear, we noted the presence of cells
bearing the same surface immunophenotype as previously
described murine SSCs (Lin-Thy-CD200+ CD105- cells)3,36
present in bone marrow aspirates (BMA). The osteogenic
potential of this population was substantially decreased when
treated with the CK2 inhibitor (i-CK2, Casein Kinase II inhibitor
IV) (Supplementary Fig. 3). Thus, CK2 is important for differ-
entiation of SSCs into osteoblasts and RUNX2 activation.
As CK2 is a constitutively active kinase, it is primarily
transcriptionally regulated37,38. Accordingly, both mRNA and
protein levels of CK2 subunits increased during osteoblast
differentiation, whereas their expression was downregulated in
mature chondrocytes and adipocytes (Fig. 1g and Supplementary
Fig. 2b–e). When cultured under chondrogenic conditions,
CSNK2B-deficient BMSCs showed an increase in chondrogenic
potential evidenced by larger chondrocyte pellet size and
upregulated expression of chondrogenic genes (Fig. 1h, i).
Likewise, under adipogenic conditions, formation of lipid
droplets and expression of adipogenic genes were markedly
upregulated by CSNK2B-deficiency (Fig. 1j, k). These results
suggest that CK2 promotes osteoblast differentiation while it
suppresses differentiation into chondrocytes or adipocytes.
CK2 is essential for skeletal development. To explore a role CK2
in skeletal development, expression of CSNK2B was examined at
the stages of early limb and postnatal skeletal development
(Supplementary Fig. 4). Immunohistochemistry (IHC) demon-
strates the expression of CSNK2B in precursor cells residing in
the perichondrium, osteoblasts in the trabecular bone, and
chondrocytes in the growth plate at postnatal day 10 (P10).
Its expression was also detected at the tip of the limb bud of
E11.5 mouse embryos. Thus, CSNK2B is expressed throughout
skeletal development from early embryonic stage to postnatal
stage. Next, we conditionally deleted Csnk2b in the mesenchyme
by crossing Csnk2b (Csnk2bfl/fl)39,40 floxed allele with a Prx1-
Cre41 (Csnk2bPrx1). Csnk2b deletion was validated in the limbs
dissected from P0 Csnk2bPrx1 neonates (Fig. 2a). Severe limb
shortening was observed in E16.5 and P0 Csnk2bPrx1 pups and P0
Csnk2bPrx1 pups died after the birth due to respiratory distress
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(Supplementary Fig. 5a). Alizarin red and alcian blue staining of
skeletal preparations revealed that ossification (red) was markedly
reduced in the calvaria, scapula, humerus, radius, ulna, femur,
tibia, fibula, digit, and sternum of Csnk2bPrxl pups while cartilage
(blue) is normally formed in skeleton (Fig. 2b, c and Supple-
mentary Fig. 5b–f). Moreover, the clavicles of Csnk2bPrxl pups
were hypoplastic (Fig. 2c, bottom, and Supplementary Fig. 5c,
top). Likewise, endochondral ossification of long bones was
arrested at the earliest stages of primary ossification center for-
mation (Fig. 2d, e and Supplementary Fig. 5g, h). These skeletal
phenotypes are similar to those seen in Runx2Prx1 pups5, sug-
gesting that CK2 is required for RUNX2 regulation.
Skeletal development occurs through a hierarchy of bone
lineage-specific progenitors, and these progenitors can be isolated
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from mouse limbs based on the expression of cell surface
markers3. Among these progenitors, we isolated homogenous
populations of SSCs using recently described FACS strategies3
from the limbs of E17.5 Csnk2bfl/fl and Csnk2bPrx1 embryos
(Supplementary Fig. 6). Csnk2b was efficiently deleted in
Csnk2bPrx1 SSCs (Fig. 2f). Absolute numbers of SSCs were
comparable between Csnk2bfl/fl and Csnk2bPrx1 embryonic limbs
(Fig. 2g). However, while little cell death of these cells was
observed, cell proliferation rate in Csnk2bPrx1 SSCs was slightly
reduced in the culture (Supplementary Fig. 7a, b), implicating a
potential role of CK2 in SSCs during embryonic development. To
determine their osteogenic potential in vivo, Csnk2bfl/fl and
Csnk2bPrx1 SSCs were transplanted into the kidney capsule of
secondary hosts and bone formation was assessed by microCT
and histology. The transplanted Csnk2bPrx1 SSCs displayed a
significant reduction in osteogenic potential despite engrafting
and expanding within the kidney capsule (Fig. 2h–j). These
findings suggest that CK2 is critical for SSC differentiation into
osteoblasts but is dispensable for SSC survival.
CK2 deletion causes CCD. To investigate the role of CK2 in
osteoblast differentiation in vitro, primary calvarial osteoblasts
(COBs) were isolated from P5 Csnk2bfl/fl pups and infected with
lentiviruses expressing vector or cre recombinase. This inducible
deletion by cre induction can offer better control of the timing of
induction, and more uniformly synchronous induction of cre
activity than relying on the endogenous cre lines13,42. As expec-
ted, Cre expression mediated efficient Csnk2b deletion in
Csnk2bfl/fl COBs (Fig. 3a). In these COBs, osteoblast differentia-
tion was substantially decreased as determined by ALP activity,
mineralization, and expression of osteogenic genes, while levels of
Runx2 mRNA were not altered in the absence of Csnk2b
(Fig. 3b–d). These phenotypes were also seen in COBs isolated
from mice with deletion of Csnk2b in osteoprogenitors
(Csnk2bOsx)43,44 (Supplementary Fig. 8). Likewise, Csnk2bOsx
mice displayed osteopenia and specific phenotypes characteristic
of RUNX2 partial loss-of-function. P10 and 2-month-old
Csnk2bOsx mice displayed open calvarial fontanels, hypoplastic
clavicles, and reduced body length (Fig. 3e–h and Supplementary
Fig. 9a, b), similar to CCD seen in human patients with loss-of-
function mutations in RUNX2 or mice with Runx2
haploinsufficiency1,6,7. In addition, Csnk2bOsx mice displayed
severe osteopenia in long bones as both the relative amount of
trabecular bone and midshaft cortical bone thickness were both
substantially reduced along with an increase in bone marrow
adipocytes (Fig. 3i–k). Consistent with this, bone formation rate
(BFR), mineralization apposition rate (MAR), and osteoblast
surface per bone surface (Ob.S/BS) were decreased in Csnk2bOsx
femurs (Fig. 3l, m), demonstrating reduced differentiation of
Csnk2b-deficient osteoblasts. Numbers of tartrate-resistant acid
phosphatase (TRAP)-positive osteoclasts and serum levels of the
bone resorption marker C-terminal telopeptide type I collagen
(CTX) were unchanged in 2-month-old Csnk2bOsx mice (Sup-
plementary Fig. 9c–e). Taken together, CK2 is critical for osteo-
blast differentiation in vitro and in vivo, and loss of CK2 produces
skeletal phenotypes similar to those seen with loss of RUNX2
activity.
CK2 stabilizes RUNX2 in osteoblasts. Next, the ability of
RUNX2 to induce osteogenesis was assessed in the absence of
Csnk2b following overexpression of RUNX2. Accompanied with
its reduced transcriptional activity (Fig. 1f), RUNX2-induced ALP
activity and expression of osteogenic genes were markedly
decreased in Csnk2b-deficient COBs, demonstrating that CK2 is
required for RUNX2-mediated osteoblast differentiation (Fig. 4a,
b and Supplementary Fig. 10a). Intriguingly, Csnk2b-deficient
COBs showed a significant reduction in protein levels of RUNX2
(Fig. 4c) while ubiquitination levels of RUNX2 were substantially
increased in these cells after treatment with the proteasomal
inhibitor MG132 (Fig. 4d). Similarly, a significant reduction in
RUNX2 protein levels was seen in Csnk2bPrx1 SSCs (Supple-
mentary Fig. 7d, e) and in P0 Csnk2bPrx1 limbs and P0 Csnk2bOsx
calvaria (Fig. 4e). However, Runx2 mRNA levels were unaltered
in these cells and tissues (Supplementary Fig. 7c and Fig. 4f),
suggesting that CK2 controls RUNX2 expression at a post-
translational level.
To investigate CK2-mediated RUNX2 regulation, co-
immunoprecipitation analysis was performed in wild-type
COBs to test the physical interaction between CK2 and RUNX2
(Fig. 4g). In addition, an in vitro kinase assay using
recombinant CK2 (rCK2) and RUNX2 (rRUNX2) was per-
formed, demonstrating that CK2 directly phosphorylates
RUNX2 (Fig. 4h). Mass spectrometry using recombinant
RUNX2 (rRUNX2) and CK2 (rCK2) showed that rCK2
phosphorylated rRUNX2 at three sites clustered in the PST
(proline/serine/threonine rich) domain at the C-terminal
region of RUNX2, Thr340, Ser354, and Ser387 (human
NM_004348 pThr340, pSer354, pSer387) (Fig. 4i). T340 was
previously identified as a Protein Kinase A-mediated phos-
phorylation site45, whereas S354 and S387 have not been
identified. To determine the functional contribution of these
three phosphorylation sites to RUNX2 activity, these three sites
were substituted to alanine in every combination of
single, double, and triple mutants and their ability to induce
RUNX2 activation was analyzed by a luciferase assay. Overall,
the single or double mutants displayed only a modest effect
on RUNX2 activity, while triple mutants (Tri-A) nearly
ablated RUNX2 activity (Fig. 4j). Likewise, RUNX2-induced
Fig. 1 CK2 is required for BMSC osteoblast commitment. a Immunohistochemistry (IHC) for RUNX2 in human HO tissue. IgG was used for negative
staining. Scale bar, 100 μm. b–d Human BMSCs expressing control shRNA (shCtrl) or shRNAs targeting CSNK2A1, -2A2, or -2B (shCSNK2A1, shCSNK2A2,
shCSNK2B) were cultured under osteogenic conditions. ALP activity was examined at day 7 (b), mineralization activity was assessed by alizarin red staining
at day 14 (c), and expression of osteogenic genes was assessed by RT-PCR at day 12 (d) after osteogenic culture. b n= 14; c, n= 8; d, n= 4 biologically
independent samples. shCtrl or shCSNK2B-expressing human BMSCs (e) and shCtrl or shCsnk2b-expressing C3H10T1/2 cells (f) were transfected with the
RUNX2-responsive reporter gene (OG2-luc) and Renilla in the absence (e) or in the presence (f) of RUNX2 overexpression. Three days after osteogenic
culture (e) or 2 days after transfection (f), OG2-luc activity was measured and normalized to a Renilla. (n= 3 biologically independent samples). g Diagram
depicting kinetics of CK2 expression over the differentiation of human BMSCs. h, i shCtrl or shCSNK2B-epxressing human BMSCs were cultured under
chondrogenic conditions for 21 days. After alcian blue staining, the size of chondrocyte pellets was measured (h). mRNA levels of chondrogenic genes were
assessed by RT-PCR (i). Scale bar, 300 μm (h). h n= 5 (shCtrl) or 6 (shCSNK2B); i n= 4 biologically independent samples. j, k shCtrl or shCSNK2B-
epxressing human BMSCs were cultured under adipogenic conditions for 12 days. Cells were stained with oil red O (j) and mRNA levels of adipogenic
genes were assessed by RT-PCR (k). Scale bar, 100 μm (j). k n= 4 biologically independent samples. Data are representative of two (a) or three (b–f, h–k)
independent experiments. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test (a) and a two-tailed unpaired Student’s t test for
comparing two groups (c–f, h, i, k; error bars, SD of biological replicates).
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ALP activity and expression of osteogenic genes were
substantially reduced in Tri-A-RUNX2 mutant-expressing
COBs (Fig. 4k and Supplementary Fig. 10b), demonstrating
that CK2-induced phosphorylation is crucial for RUNX2-
mediated osteoblast differentiation. As observed in Csnk2b-
deficient SSCs and osteoblasts, protein levels of Tri-A-RUNX2
were markedly reduced relative to WT-RUNX2 despite showing
a slight elevation in the corresponding mRNA levels (Fig. 4l,
m). This reduction in protein levels was accompanied by an
increase in ubiquitination of the RUNX2-Tri-A mutant
(Fig. 4n), suggesting that an increased susceptibility of the
Tri-A-RUNX2 mutant to proteasomal degradation is
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responsible for its decreased function. Thus, CK2-induced
phosphorylation mediates RUNX2 stabilization in osteoblasts
by counteracting ubiquitin-dependent proteasomal degradation
of RUNX215–17.
HAUSP controls osteogenesis via RUNX2 stabilization. To
identify potential regulators of RUNX2 ubiquitination in osteo-
blasts, affinity purification using Flag-RUNX2 (WT or Tri-A)
followed by mass spectrometry was performed after balancing the
expression of these two constructs (Supplementary Fig. 11a).
Ingenuity pathway analysis (IPA) of RUNX2-binding proteins
identified enrichment of several signaling pathways including the
protein ubiquitination pathway (red, Fig. 5a). Specifically, this
identified SMURF1, a known ubiquitin E3 ligase of RUNX215,
and the ubiquitin-specific protease (USP) family including
HAUSP, USP9x, USP10, and USP47, as potential RUNX2-
binding partners. Expression intensity of these USPs was mark-
edly reduced in the eluate of Flag-RUNX2 (Tri-A) relative to
Flag-RUNX2 (WT) (Supplementary Fig. 11b), suggesting that
CK2-induced phosphorylation recruits these USPs to RUNX2.
Knockdown studies in human BMSCs were used to determine
which of these CK2-dependent RUNX2 interaction partners are
important for osteoblast differentiation (Fig. 5b). Knockdown of
HAUSP or USP24 but not USP9x or USP10 resulted in a sig-
nificant reduction in ALP activity, mineralization, and expression
of osteogenic genes (Fig. 5b–d and Supplementary Fig. 11c).
Notably, similar to CK2, knockdown of HAUSP decreased pro-
tein but not mRNA levels of RUNX2 (Fig. 5e, f). HAUSP is an
evolutionarily conserved deubiquitinating enzyme (DUB) and
plays role in multiple cellular process46. However, the function of
HAUSP in osteoblast biology remains largely unknown.
In vitro deubiquitination assays demonstrate that ubiquitina-
tion levels of RUNX2 were substantially reduced by either
enforced expression of HAUSP or the addition of recombinant
HAUSP (rHAUSP) (Fig. 5g, h). Furthermore, co-
immunoprecipitation confirmed an interaction between HAUSP
and RUNX2 (Fig. 5i). However, unlike HAUSP, USP24 was
unable to interact with RUNX2 and reduce ubiquitination levels
of RUNX2 (Supplementary Fig. 12), suggesting that HAUSP, not
USP24, functions as a bona-fide RUNX2-DUB. This process
requires CK2-induced phosphorylation, as the interaction
between RUNX2 and HAUSP was markedly reduced in the
presence of the RUNX2-Tri-A mutation (Fig. 5i). Likewise, the
interaction between rRUNX2 and rHAUSP was enhanced in a
cell-free system by the addition of rCK2 and ATP but not rCK2
alone (Fig. 5j). In addition, while enforced expression of HAUSP
increased protein levels of RUNX2-WT, the RUNX2-Tri-A
mutant was largely refractory to HAUSP-induced stabilization
(Fig. 5k). Taken together, CK2-induced phosphorylation of
RUNX2 recruits HAUSP, stabilizing RUNX2 through deubiqui-
tination (Fig. 5l).
Hausp haploinsufficiency causes CCD. Similar to knockdown of
HAUSP in human BMSCs, Hausp-deficient COBs show a
markedly decreased ability to induce osteoblast differentiation as
determined by a significant reduction in expression of osteogenic
genes, ALP activity, and mineralization (Fig. 6a–c). In addition,
RUNX2 protein was reduced in Hausp-deficient COBs without
alteration of the corresponding mRNA levels (Fig. 6d, e), similar
to the phenotypes shown in Csnk2b-deficient COBs. Accordingly,
Hausp-deficient osteoblasts were refractory to RUNX2-induced
transcriptional activation (Fig. 6f) and osteoblast differentiation
(Fig. 6g, h and Supplementary Fig. 13a). Thus, HAUSP is per-
missive for osteoblast differentiation through stabilization of
RUNX2.
Since the function of HAUSP in skeletal development was
undefined, expression of HAUSP was examined in limb bud
from E11.5 embryo and skeletal components (perichondrium
cells, osteoblasts, and chondrocytes) from P10 mouse, and it
showed similar expression aspects found in CSNK2B expression
(Supplementary Fig. 4). To investigate a role of HAUSP in
osteoblasts in vivo, Hauspfl/fl mice were crossed with Osx-Cre
mice. Due to the extremely low birth rate of pups with
homozygous deletion of Hausp (HauspOsx), skeletal phenotypes
were studied in mice with a heterozygous deletion of Hausp
(Hausp+/Osx) (Fig. 6i). As observed in Runx2+/− and Csnk2bosx
mice, Hausp+/Osx mice developed CCD phenotypes, as
characterized by open fontanels, hypoplastic clavicles, and
short stature (Fig. 6j, k). In addition, substantial osteopenia was
observed in both the trabecular and cortical compartments,
which was accompanied by an increase in bone marrow
adipocytes (Fig. 6l–n). However, numbers of TRAP-positive
osteoclasts and resorption activity in the metaphysis of
trabecular bone were not altered in Hausp+/Osx mice relative
to Osx-Cre or Csnk2b+/Osx mice (Supplementary Fig. 13c, d),
demonstrating that osteoclasts are normal in Hausp+/Osx mice.
Thus, similar to CK2, HAUSP controls osteoblast differentia-
tion via RUNX2 stabilization.
Finally, we investigated whether CK2 and HAUSP cooperate to
control the RUNX2 pathway in vivo. The genetic interaction between
RUNX2, CK2, and HAUSP was examined by comparing skeletal
phenotypes of Osx-Cre, Csnk2b+/Osx, Hausp+/Osx, Csnk2b+/Osx;
Hausp+/Osx, Runx2+/Osx, Runx2+/Osx;Csnk2b+/Osx, and Runx2+/Osx;
Hausp+/Osx mice (Fig. 6o, p and Supplementary Fig. 13b). The CCD
phenotypes seen in Hausp+/Osx mice became more pronounced by
additional heterozygous deletion of Csnk2b (Csnk2b+/Osx;Hausp+/Osx
mice) (Fig. 6o). Of note, chondrocyte development in the
growth plate is relatively normal in these mice (Supplementary
Fig. 13e). Likewise, addition of heterozygous deletion of
Csnk2b (Runx2+/Osx;Csnk2b+/Osx mice) or Hausp (Runx2+/Osx;
Hausp+/Osx mice) results in more severe CCD phenotypes in
Runx2+/Osx mice (Fig. 6p). Thus, these results suggest that CK2
and HAUSP operate in the same pathway to regulate RUNX2 in
osteoprogenitors.
Fig. 2 CK2 is required for bone formation during skeletal development. a Csnk2b mRNA levels in the hindlimbs (femur and tibia) of E17.5 Csnk2bfl/fl and
Csnk2bPrx1 embryos. (n= 4). b, c Alizarin red/alcian blue staining of skeletal preparations of E17.5 Csnk2bfl/fl and Csnk2bPrx1 embryos. Scale bar, 1 mm.
Safranin O staining of humeri (d) and femurs (e) of P0 Csnk2bfl/fl and Csnk2bPrx1 pups. Scale bars, 250 μm (left) and 50 μm (right, enlarged one). f, g
Csnk2b mRNA levels in SSCs (CD45−Ter119−Tie2−αV-Int+Thy1−6C3−CD105−CD200+) isolated from E17.5 Csnk2bfl/fl and Csnk2bPrx1 embryos (f).
Frequency of SSCs within the population of total skeletal cells (CD45−Ter119−Tie2−αV-Int+) (g). f n= 4; g, n= 6 (Csnk2bfl/fl) or 5 (Csnk2bPrx1)). h–j SSCs
(CD45−Ter119−Tie2−αV-Int+Thy1−6C3−CD105−CD200+) isolated from E17.5 Csnk2bfl/fl and Csnk2bPrx1 embryonic limbs were transplanted beneath the
kidney capsule. MicroCT analysis shows 3D-reconstruction (h) and quantification (i) of bone mass in the kidney capsule. BV bone volume. Histologic
sections of kidney capsule were stained with H&E (j, left) or Von Kossa (j, right). The arrow highlights the ectopic bone. Scale bars, 200 μm (h); 100 μm (j).
i n= 7 or 14. Data are representative of three (a–e, h, j) independent experiments or are pooled from two experiments (f, g, i). A two-tailed unpaired
Student’s t test for comparing two groups (a, f, g, i; error bars, SD of biological replicates).
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Inhibition of the CK2-HAUSP pathway suppresses HO. IHC on
human HO tissue identified expression of CSNK2A and HAUSP
in osteoblasts on the surface of heterotopic bone (Fig. 7a), which,
when taken together with the expression of RUNX2 in the same
tissue (Supplementary Fig. 1b), suggests that the CK2-HAUSP-
RUNX2 pathway is intact at sites of HO. Expression levels of
Csnk2a1 and Hausp were all markedly upregulated at the site of
injury in a mouse model of acquired HO (Fig. 7b). Thus, we
hypothesized that RUNX2 stabilization by the CK2-HAUSP
pathway contributes to the pathogenesis of HO and that
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inhibition of this pathway may prevent HO. To test this, mouse
models representing the highest incidence forms of HO, muscle
injury/BMP-induced HO29,47 and burn injury/Achilles tenotomy-
induced HO48,49, were employed in Csnk2bfl/fl, Osx-Cre, and
Csnk2bOsx mice. In Csnk2bfl/fl and Osx-Cre control mice, HO
occurred 3 weeks after blunt muscle trauma and administration
of recombinant BMP2/7 (BMP2/7) (muscle injury/BMP-induced
HO; Fig. 7c). Likewise, Achilles tenotomy following a remote
burn injury resulted in HO at the tenotomy site 8 weeks post
injury (burn/Achilles tenotomy-induced HO; Fig. 7f). Heterotopic
bone was formed via an endochondral pathway including for-
mation of cartilage and adipose tissues and recruitment of
hematopoietic elements (Fig. 7e, left and h, top). By contrast,
Csnk2bOsx mice displayed a significant reduction in HO while
cartilage or adipose tissue was still formed at the injury site
(Fig. 7c–h), demonstrating that CK2 is required for heterotopic
bone formation in mouse models of acquired HO. Notably,
protein levels of RUNX2 were markedly decreased in the HO
areas of Csnk2bOsx mice relative to Csnk2bfl/fl mice while its
mRNA levels were comparable in these HO tissues (Supple-
mentary Fig. 14b–g). Thus, these results suggest that CK2-
mediated stabilization of RUNX2 is important for the develop-
ment of HO.
We next tested whether pharmacological inhibition of the
CK2-HAUSP pathway can suppress HO development. Consistent
with observations in Csnk2b-deficient COBs, treatment with a
small molecule inhibitor of CK2 (i-CK2) reduced BMP2/7-
induced ALP activity and mineralization and RUNX2 transcrip-
tion activity (Supplementary Fig. 15a–c). Similarly, BMP2/7-
induced ALP and mineralization activity and RUNX2 protein
levels were decreased in osteoblasts by treatment with a small
molecule inhibitor of HAUSP (i-HAUSP, HBX41108) while levels
of RUNX2 mRNA were not altered (Supplementary Fig. 15d–f).
Next, we tested whether pharmacological inhibition of the CK2-
HAUSP pathway can suppress ectopic bone formation in mouse
models of HO. One day after either muscle injury/BMP2/7
injection or burn injury/tenotomy, WT mice were treated daily
with a CK2 inhibitor or a HAUSP inhibitor and HO was assessed
by microCT (Fig. 7i–l). As expected, vehicle-treated mice
developed heterotopic bone at the sites of injured muscle 3 weeks
after muscle injury and BMP2/7 injection or 8 weeks after burn
injury and Achilles tenotomy. However, when treated with either
a CK2 or HAUSP inhibitor, HO was substantially reduced at the
sites of injury in both mouse models. These results provide proof-
of-principle that inhibition of the CK2-HAUSP-RUNX2 pathway
has therapeutic potential to prevent HO. Taken together, the
CK2-HAUSP-RUNX2 pathway is a key regulator of osteoblast
differentiation and both orthotopic and heterotopic bone
formation.
Discussion
This study identifies that a CK2/HAUSP pathway stabilizing
RUNX2 is essential for both physiologic and pathologic bone
formation. Mechanistically, CK2 phosphorylates RUNX2 at T340,
S354, and S387 and phosphorylated RUNX2 in turn recruits the
DUB HAUSP, which stabilizes RUNX2 by counteracting
ubiquitin-dependent proteasomal degradation (Fig. 5l). Previous
studies have shown that ubiquitin E3 ligases, including SMURF1,
SMURF2, or WWP1 induce ubiquitin-dependent proteasomal
degradation of RUNX2 in osteoblasts and their deficiency in
osteoblasts enhances osteoblast differentiation15–17. As CK2-
induced phosphorylation of RUNX2 does not alter its interaction
with these E3 ligases (Supplementary Fig. 11b), the CK2-HAUSP
pathway is likely to operate as an independent, orthogonal
mechanism for RUNX2 regulation. Lastly, this study discovers
HAUSP as the DUB that stabilizes RUNX2 by suppressing ubi-
quitin E3 ligase-mediated ubiquitination. We note that, while we
identify RUNX2 as a critical substrate for both CK2 and HAUSP
in this study, both proteins are likely to have additional substrates
that contribute to their regulation of osteogenesis.
HO can result in severely impaired functional recovery after
injury as heterotopic bone spans across joints to limit their
mobility29–31. Existing therapeutic approaches include bispho-
sphonates, external beam radiation, or nonsteroidal anti-
inflammatory drugs, however each of these approaches can pre-
vent healing of concurrent skeletal injuries and each can be
complicated by either suboptimal efficacy or rare but potentially
severe toxicities32,50–52. Given the relatively high incidence of
HO, there is an urgent need to develop improved therapeutic
agents. The evidence that RUNX2 expression was highly upre-
gulated in both human and mouse HO tissues and that its inhi-
bition prevented HO in mice implies that RUNX2 plays a role in
the pathogenesis of HO8–11. Here, we identify a CK2-HAUSP
pathway as a druggable pathway that controls RUNX2 for the
treatment of HO. Development of acquired HO in two estab-
lished models, muscle injury/BMP-induced HO29,47 and burn
injury/Achilles tenotomy-induced HO48,49 was suppressed by
Csnk2b deletion in osteoblasts or by treatment with either a CK2
or HAUSP inhibitor, providing proof-of-principle that inhibition
of the CK2-HAUSP-RUNX2 pathway has therapeutic potential to
prevent HO. Nonetheless, the long-term therapeutic outcomes
and adverse effects of these inhibitors in treating HO require
further investigation, as CK2 and HAUSP are involved in diverse
cellular processes in addition to osteogenesis.
Fig. 3 CK2 is required for maturation of osteoprogenitors in vitro and in vivo. a–d COBs isolated from P5 Csnk2bfl/fl pups were infected with lentiviruses
expressing vector (WT) or Cre recombinase (Csnk2b KO) and cultured under osteogenic conditions. mRNA levels of Csnk2b (a) and osteogenic genes (d)
were measured by RT-PCR at day 12. ALP activity (b, left) and staining (b, right) or alizarin red staining (c) were performed at day 7 or 18, respectively.
Scale bar, 250 μm (b). a, d, n= 4; b, c, n= 6. e Csnk2b mRNA levels in P0 calvaria of Csnk2bfl/fl, Osx-Cre, and Csnk2bOsx pups. (n= 4). f Alizarin red/alcian
blue staining of skeletal preparations of calvaria (top) and clavicles (bottom) obtained from P10 Csnk2bfl/fl, Osx-Cre, and Csnk2bOsx pups. Scale bar,
2 mm. g MicroCT analysis shows 3D-reconstruction of calvaria from 2-month-old Csnk2bfl/fl, Osx-Cre, and Csnk2bOsx male mice. The arrows indicate
hypomineralization areas. Scale bar, 2 mm. h Radiographic images of clavicles from 2-month-old Osx-Cre and Csnk2bOsx male mice. The arrow indicates
defective sternoclavicular ossification. Scale bar, 2 mm. i, j MicroCT analysis of femurs from 2-month-old Csnk2bfl/fl, Osx-Cre, and Csnk2bOsx male mice.
Quantification (i) and 3D-reconstruction (j) are displayed. Trabecular bone volume/total volume Tb. BV/TV trabecular thickness, Tb.Th trabecular number
per cubic millimeter, Tb.N, and C.Th cortical thickness. Scale bar, 1 mm (j). i Tb. BV/TV, Tb.Th, Tb.N; n= 12 (Csnk2bfl/fl), 7 (Osx-Cre) or 5 (Csnk2bOsx), C.Th;
n= 13 (Csnk2bfl/fl), 5 (Osx-Cre) or 5 (Csnk2bOsx)). k H&E-stained longitudinal sections of femurs from 2-month-old Osx-Cre and Csnk2bOsx male mice. Scale
bar, 50 μm. l, m Histomorphometric analysis of femurs from 2-month-old Osx-Cre and Csnk2bOsx female mice. Images of calcein/alizarin red-labeled
sections of the femur (l) and quantification (m) are displayed. Scale bar, 50 μm (l). BFR/BS bone formation rate per bone surface, MAR mineral reposition
rate, Ob.S/BS osteoblast surface per bone surface. (n= 9 (Osx-Cre) or 8 (Csnk2bOsx)). Similar skeletal phenotypes were observed in both male and female
mice (f–m). Data are representative of three (a–h, j–l) independent experiments or are pooled from two experiments (i, m). A two-tailed unpaired
Student’s t test for comparing two groups (a–e, i, m; error bars, SD of biological replicates).
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CK2 is a highly conserved serine/threonine kinase that is
involved in various cellular processes. However, in vivo roles for
CK2 in the skeleton are largely unknown. In contrast to previous
in vitro studies showing that a CK2 inhibitor (CX-4945) or
peptides that interfere with the interaction between CK2 and
BMPRIa enhanced BMP-induced osteogenesis27,28,53,54, we here
find genetic evidence that orthotopic and heterotopic bone for-
mation were substantially reduced in the absence of Csnk2b.
Furthermore, in contrast to a previous study showing inhibitory
effects of CX-4945 treatment on RANKL-induced osteoclast dif-
ferentiation in vitro28, osteoclast differentiation and bone mass
are normal in mice lacking Csnk2b in osteoclasts (Csnk2bfl/fl;
Cathepsin K-cre, Supplementary Fig. 16a), suggesting that CK2 is
dispensable for osteoclast activity in vivo. Notably, unlike osteo-
blasts, CK2 expression was not upregulated during osteoclast
differentiation (Supplementary Fig. 16b). Thus, CK2 functions as
a positive regulator of osteoblast differentiation with a function
specific for osteoblast-lineage cells.
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The vascular development in the skeletal system is essential for
physiologic bone formation and skeletal fracture repair55–57.
Osteoblast-derived angiogenic factors, such as vascular endothe-
lial growth factor (VEGF)55, erythropoietin (EPO)58 and SLIT357,
are crucial for this process. Given that CK2 plays a positive role in
angiogenesis59–61, Csnk2b-sufficient and -deficient COBs were
cultured under undifferentiation or osteogenic conditions and
subjected for transcriptome analysis, demonstrating down-
regulation of a subset of the genes related to angiogenesis and
vasculogenesis in the absence of Csnk2b (Supplementary Fig. 17).
Of note, expression of key osteoblast-derived angiogenic factors,
including Vegfa, Epo, and Slit3 and hypoxia-inducible factor-1
alpha, a key component that mediates reciprocal interaction
between angiogenesis and osteogenesis62, was not altered in the
absence of Csnk2b. Csnk2b-deficient osteoblasts show reduced
expression of antiangiogenic factor chemokine (C-X-C motif)
ligand 9 (Cxcl9)63 (Supplementary Fig. 18). Accordingly, cell
migration and tube formation of endothelial cells were relatively
comparable in the culture of conditioned medium (CM) obtained
from Csnk2b-sufficient or -deficient COBs (Supplementary
Fig. 19). These results suggest that osteoblast CK2 activity is
dispensable for regulation of angiogenesis and raise the possibility
that CK2-mediated regulation of factors traditionally associated
with angiogenesis may instead here couple to other functional
processes.
Methods
Plasmids, antibodies, and cell culture. Plasmid for Flag/HA-HAUSP was
deposited to Addgene by Bert Vogelstein (#16655). HA-HAUSP was generated by
sub-cloning from this source. The construct for HA-UBB (Ubiquitin) was depos-
ited to Addgene by Edward Yeh (#18712) and plasmid for His-Ubiquitin was
generated by sub-cloning. All constructs encoding shRNAs were purchased from
Sigma. CK2-phosphorylation sites (human NM_004348 pThr340, pSer354,
pSer387) were substituted to alanine in every combination of single, double, and
triple mutants on human RUNX2 cDNA13 using Quikchange Multi Site-Directed
Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s
instructions.
Antibodies specific to HAUSP (sc-30164), GAPDH (sc-25778), HSP90 (sc-
7947), or ubiquitin (sc-8017) were purchased from Santa Cruz Biotechnology.
Antibodies specific to CSNK2A (Cell signaling, 2656), CSNK2B (Abcam,
ab133576), RUNX2 (Calbiochem, PC287; Cell signaling, 12556), and USP24
(Proteintech, 13126-1-AP) were used according to manufacturers’ instructions.
Recombinant human BMP2/7 (3229-BM) was purchased from R&D systems.
Lastly, inhibitors of CK2 (CK2 inhibitor IV and CX-4945) were purchased from
Calbiochem (218713) and Selleckchem (S2248), respectively. HAUSP inhibitor
(HBX41108, 428510) was purchased Tocris Bioscience.
C3H10T1/2 and HEK293T cells were purchased from ATCC and grown in
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1% penicillin/
streptomycin and 1% nonessential amino acids. Human BMSCs (CD29+, CD44+,
CD105+, CD34−, CD45−) were purchased from Cyagen Biosciences and
were maintained in the growth medium (HUXMX-90011) and cultured in
osteogenic medium (GUXMX-90021), chondrogenic medium (GUXMX-90041),
or adipogenic medium (GUXMX-90031) according to the manufacturer’s
instructions. To confirm chondrocyte differentiation, the chondrocyte pellets
were harvested on days 21 and washed with phosphate-buffered saline (PBS), then
stained with 1% of alcian blue solution for (Sigma, A3157). To examine adipocytes
differentiation and lipid droplet formation, the differentiated cells were fixed with
4% of paraformaldehyde (PFA) for 2 h on ice, then stained with 0.3% of oil red O
solution (Sigma, O0625) for 1 h on ice.
Primary Csnk2b- or Hausp-deficient osteoprogenitors (COBs) were isolated
from calvaria of 5-day-old Csnk2bfl/fl or Hauspfl/fl neonates, respectively, using
collagenase type II (50 mg/ml, Worthington, LS004176)/dispase II (100 mg/ml,
Roche, 10165859001) and transduced with either lentiviruses expressing EGFP
(control) or cre recombinase13. At 48 h after infection, COBs were treated with
puromycin for selection. COBs were maintained in α-MEM medium (Gibco)
containing 10% FBS (Gibco), 2 mM L-glutamine (Corning), 1% penicillin/
streptomycin (Corning), and 1% nonessential amino acids (Corning) and
differentiated with ascorbic acid (200 uM, Sigma, A8960) and β-glycerophosphate
(10 mM, Sigma, G9422).
Human subjects and HO analysis. De-identified heterotopic bone samples were
obtained from human patients in Yonsei University Severance Hospital, Korea
under institutional review board approval (IRB No.4-2017-1223). The individuals
included three patients (one male and two females, previously healthy, nonsmoking
individuals; age ranging from 29 to 67 years) with pain or decreased hip movement.
The specimens that show spontaneous HO radiographically and pathologically
were used for histology and IHC.
Isolation of human SSCs. Human BMA purchased from StemExpress
(BMEDT010F) was incubated for 10 min at room temperature with BD Pharm
Lyse hypotonic lysis buffer (BD Biosciences, 555899) for RBC lysis. Cells were
washed with cold FACS buffer twice, incubated with Fc blocking buffer (BD
biosciences, 564765) for 15 min at 4 °C, and treated with antibody cocktail
including CD31 (1:100, BD biosciences, 560984), CD45 (1:100, BD biosciences,
560976), CD235a (1:100, BD biosciences, 561017), CD90 (1:100, BD biosciences,
566219), CD200 (1:100, BD biosciences, 564114), CD105 (1:100, BioLegend,
323217) in brilliant stain buffer (BD biosciences, 563794). After treatment with
DAPI, cells were subjected for FACS analysis using a Becton Dickinson Aria II
equipped with five lasers (BD biosciences). The data were analyzed using FlowJo
(v.10.1). The strategy to sort skeletal progenitors is diagrammed in Supplementary
Fig. 3.
Mice. Csnk2bfl/fl mice were previously reported39 and maintained on C57BL/6
background. Hauspfl/fl mice were generated and maintained on a mixed back-
ground of 129Sv and C57BL/6J64,65. Runx2 fl/fl mice were previously reported5.
Transgenic mice expressing Cre recombinase under the control of the prx1 pro-
moter (Prx1-cre)41 or the osterix promoter (Osx-cre)43 were purchased from
Jackson laboratory and were crossed with Csnk2bfl/fl mice or Hauspfl/fl mice.
Transgenic mice expressing Cre recombinase under the control of the Cathepsin K
promoter (Ctsk-cre) were a gift from Dr Takashi Nakamura (Tokyo Dental Col-
lege, Japan). Mouse genotypes were determined by PCR on tail genomic DNA;
primer sequences are available upon request. Both male and female mice were used
and analyzed in all experiments. Control littermates were analyzed in all experi-
ments. All animals were used in accordance with the NIH Guide for the Care and
Use of Laboratory Animals and were handled according to protocols approved by
the Weill Cornell Medical College subcommittee and the University of Massa-
chusetts Medical School on animal care (IACUC).
Fig. 4 CK2-induced phosphorylation is required for RUNX2 stabilization in osteoblasts. a–c Csnk2b-sufficient or -deficient COBs were infected with
lentiviruses expressing vector- or RUNX2 and cultured under osteogenic conditions for 6 days. ALP activity (a), mRNA levels of osteogenic gene (b), and
protein levels of RUNX2 (c) were assessed. a n= 6; b, n= 4 biologically independent samples. d shCtrl or shCsnk2b-expressing C3H10T1/2 cells were
transfected with Myc-RUNX2. 2 days after transfection, cells were treated with 10 μMMG132 for 6 h, lysed, immunoprecipitated with anti-Myc conjugated
agarose, and immunoblotted with anti-ubiquitin antibody. Protein (e) and mRNA (f) levels of Runx2 in P0 Csnk2bfl/fl and Csnk2bPrx1 limbs (top) and P0
Csnk2bfl/fl and Csnk2bOsx calvaria (bottom). f n= 4 biologically independent samples). g Wild-type COBs were lysed, immunoprecipitated with anti-IgG
control or anti-RUNX2 antibody and protein G-conjugated agarose, and immunoblotted with the indicated antibodies. Asterisk indicates CSNK2B; double
asterisks indicate RUNX2; WCL whole cell lysate. h The kinase activity of CK2 was assessed by a cell-free kinase assay using recombinant CK2 (rCK2) and
RUNX2 (rRUNX2). i A diagram depicting CK2-induced phosphorylation sites on RUNX2 as determined by phospho-mass spectrometry. j C3H10T1/2 cells
were transfected with vector, RUNX2-WT or RUNX2-Tri-A mutant along with OG2-luc and Renilla. 2 days after transfection, OG2-luc activity was measured
and normalized to Renilla. (n= 6). kWild-type COBs were infected with lentiviruses expressing vector, RUNX2-WT or RUNX2-Tri-A mutant, cultured under
osteogenic conditions for 6 days, and ALP activity was measured. (n= 6). RUNX2-WT or Tri-A mutant was transfected into C3H10T1/2 cells and 2 days
later, protein (l) and mRNA (m) levels of RUNX2 were assessed. m n= 4. n HEK293T cells were transfected with vector, RUNX2-WT or RUNX2-Tri-A
mutant along with His-ubiquitin. 2 days after transfection, cells were treated with 10 μM MG132 for 6 h, lysed, immunoprecipitated with Ni-NTA agarose,
and immunoblotted with anti-RUNX2 antibody. Data are representative of three (a–h, j–n) independent experiments. A two-tailed unpaired Student’s t test
for comparing two groups (a, b, f, m) and ordinary one-way ANOVA with Sidak’s multiple comparisons test (j, k; error bars, SD of biological replicates).
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MicroCT, radiography, and skeletal preparation. MicroCT was used for quali-
tative and quantitative assessment of trabecular and cortical bone micro-
architecture and performed by an investigator blinded to the genotypes of the
animals under analysis. Femurs excised from the indicated mice were scanned
using a microCT 35 (Scanco Medical) with a spatial resolution of 7 μm. For tra-
becular bone analysis of the distal femur, an upper 2.1 mm region beginning
280 μm proximal to the growth plate was contoured. For cortical bone analysis of
femur and tibia, a midshaft region of 0.6 mm in length was used. MicroCT scans of
skulls, kidneys, and HO in muscle/achilles tendon were performed using isotropic
voxel sizes of 12 μm. 3D-reconstruction images were obtained from contoured 2D
images by methods based on distance transformation of the binarized images. All
images presented are representative of the respective genotypes (n > 5).
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Radiographic images of clavicles were taken by the Faxitron Specimen
Radiography System Model Mx-20 at 26 kV for 20 s.
Skeletons were prepared for analysis of gross morphology using the method of
McLeod66. Briefly, mice were sacrificed, skinned, eviscerated, and fixed in 95%
ethanol for a day. Then, skeletons were stained by alizarin red S and alcian blue
(Sigma, A3157) solutions and sequentially cleared in 1% potassium hydroxide. All
images presented are representative of the respective genotypes (n > 5).
Histology, histomorphometry, and IHC. For histological analysis, hindlimbs were
dissected from the mice, fixed in 10% neutral buffered formalin for 2 days, and
decalcified by daily changes of 15% tetrasodium EDTA for 1–2 weeks. Tissues were
dehydrated by passage through an ethanol series, cleared twice in xylene,
embedded in paraffin, and sectioned at 7-μm thickness along the coronal plate
from anterior to posterior. Decalcified femoral sections were stained with hema-
toxylin and eosin (H&E), safranin O, or TRAP.
For histomorphometric analysis, 25 mg/kg calcein (Sigma, C0875) and 50 mg/
kg alizarin-3-methyliminodiacetic acid (Sigma, A3882) dissolved in 2% sodium
bicarbonate solution were subcutaneously injected into mice at 5 day-interval.
After 2 day-fixation in 10% neutral buffered formalin, undecalcified femur samples
were embedded in methylmethacrylate. Proximal metaphysis was sectioned
longitudinally (5 μm) and stained with McNeal’s trichrome for osteoid assessment,
toluidine blue for osteoblasts, and TRAP for osteoclasts67. A region of interest is
defined and bone formation rate/bone surface (BFR/BS), MAR, bone area (B.Ar),
and osteoclast number/bone parameter were measured using a Nikon Optiphot 2
microscope interfaced to a semiautomatic analysis system (Osteometrics).
Measurements are taken on two sections/sample (separated by ~25 μm) and
summed prior to normalization to obtain a single measure/sample in accordance
with ASBMR standards68. This methodology has undergone extensive quality
control and validation and the results will be assessed by a research specialist in a
blinded fashion.
For IHC, paraffin sections were dewaxed and stained as following procedure
using the Discovery XT automated IHC stainer (Ventana Medical Systems, Inc.,
Tucson, AZ, USA). CC1 standard (pH 8.4 buffer contained Tris/Borate/EDTA) and
inhibitor D (3% H2O2, Endogenous peroxidase) were used for antigen retrieval
and blocking, respectively. Sections were incubated with antibodies specific to
HAUSP (1:50, ABclonal, A13564), RUNX2 (1:100, MBL, D130-3), Casein Kinase 2
beta (1:100, Abcam, ab133576), Casein Kinase 2 alpha (1:100, Abcam, ab70774) for
40 min at 37 °C, and a secondary antibody of Universal secondary antibodies for
20 min at 37 °C. Subsequently, they were incubated in SA-HRP D for 16 min at 37 °
C and then DAB+H2O2 substrate for 8 min followed by hematoxylin and bluing
reagent counterstain at 37 °C. Reaction buffer (pH 7.6 Tris buffer) was used as
washing solution. The stained samples were visualized using an Aperio virtual
microscope (Leica Microsystems, USA) and images of the sample were analyzed by
the Aperio image scope program (ver. 12.3.2.8013, Leica Microsystems, USA). For
immunofluorescence, antibodies for CSNK2B (1:100, Abcam, ab76025), RUNX2
(1:50, Santacruz, sc-390351), HAUSP (1:50, Abclonal, A13564), and COL1A1
(1:50, Abclonal, A1352) were used as primary antibodies and Alexa Fluor 488
(1:400, Thermo, A21206) and Alexa Fluor 594 (1:400, Thermo, A11032) were used
as secondary antibodies as manufacturer’s descriptions.
Kidney transplantation of SSCs. E17.5 Csnk2bfl/fl and Csnk2bPrx1 embryonic
limbs were dissociated by mechanical and enzymatic digestion (1 mg/ml of Col-
lagenase P (Roche, 11213857), 2 mg/ml of Dispase II (Roche, 10165859001), 1 mg/
ml of Hyaluronidase (Sigma, H3506) and 10000 unit/ml of DNase I (Roche,
4716728001)) for 1 h at 37 °C under gentle agitation. After digestion, cells were
passed through 40 μm cell strainer and washed with FACS buffer (cold PBS (pH
7.2) containing 0.5% BSA (Fraction V) and 1 mM EDTA). The cells were subse-
quently blocked with purified rat anti-mouse CD16/CD32 (Biolegend, 553141) for
1 h on ice and stained with Biotin-conjugated CD45 (1:200, ebioscience, 13-0451-
81), Tie2 (1:200, ebioscience, 13-5987-81) and Ter119 (1:200, ebioscience, 13-5921-
81) with BV421-conjuated streptavidin (1:500, Biolegend, 405226), PE-conjugated
CD51 (1:200, ebioscience, 12-0512-81), BV605-conjugated Thy1.1–2 (1:200, Bio-
legend, 202537/140317), APC-conjugated CD200 (1:100, Biolegend, 123809),
FITC-conjugated LY51 (1:50, Biolegend, 108305) and PE/Cy7-conjugated CD105
(1:200, Biolegend, 120409) for 45 min on ice. After washing three times, cells were
resuspended in cold PBS (pH 7.2) with 1 mM EDTA and 1 µg/ml DAPI and sorted
with a FACSAria II SORP cell sorter (Becton Dickinson) with exclusion of DAPI+
cells and doublets. The strategy to sort skeletal progenitors is diagrammed in
Supplementary Fig. 6. The sorted mouse SSCs (10,000 cells/mouse) were mixed
with 20 μl of matrigel (Corning, 354230) and injected underneath the renal cap-
sules of 8-week-old anesthetized male mice (C57BL/6). Six to eight weeks after
transplantation, renal samples were fixed in 4% of PFA and their bone mass was
assessed by microCT. For histology, they were embedded in methylmethacrylate
and stained with H&E and Von Kossa.
Cell proliferation assay. Cell proliferation was examined using bromodeoxyur-
idine (BrdU) incorporation assay (Abcam, ab126556) according to manufacturer’s
instructions.
Mouse models of acquired HO. For muscle injury/BMP-induced HO model29,47,
blunt muscle trauma was induced by dropping an aluminum ball into mouse
adductor muscle right next to femur and a mixture of recombinant BMP2/7 (1 μg)
and matrigel (20 μl) was injected into the injured area. Subcutaneous injection of
buprenorphine was provided for analgesia. Mice were euthanized and HO was
assessed by microCT and histology at 3 weeks post injury.
For burn injury/Achilles tenotomy-induce HO model48,49, ~30% total body
surface area was exposed to 60 °C heated aluminum block for 18 s, a tegaderm
dressing was applied to burn site and sterile saline solution, and buprenorphine
were subcutaneously administrated. Subsequently, mice received an Achilles
tenotomy on the right leg. Mice were euthanized and HO was assessed by microCT
and histology at 8 weeks post injury.
To test the therapeutic potential of CK2 or HAUSP inhibitor to prevent HO, 3-
month-old wild-type male mice (C57BL/6) were subjected to the HO models above
and randomly divided into different experimental groups. One day after HO injury,
mice were daily treated with DMSO (vehicle control), CK2 inhibitor (2.5 mg/kg) or
HAUSP inhibitor (2 mg/kg) via intraperitoneal (i.p.) injection for 3 weeks (muscle
injury/BMP-induced HO) or for 8 weeks (burn injury/Achilles tenotomy-induced
HO). HO tissue was harvested, fixed in 4% PFA, and HO was assessed by microCT.
Osteoblast differentiation analysis. For ALP staining, osteoblasts were fixed with
10% neutral formalin buffer and stained with the solution containing Fast Blue
(Sigma, FBS25) and Naphthol AS-MX (Sigma, 855). Alternatively, osteoblasts were
incubated with tenfold diluted Alamar Blue solution (Invitrogen, DAL1100) for cell
proliferation. Subsequently, cells were washed and incubated with a solution
containing 6.5 mM Na2CO3, 18.5 mM NaHCO3, 2 mM MgCl2, and phosphatase
substrate (Sigma, S0942), and ALP activity was measured by spectrometer (Biorad).
To assess extracellular matrix mineralization in mature osteoblasts, cells were
washed twice with PBS and fixed in 70% EtOH for 15 min at room temperature.
Fixed cells were washed twice with distilled water and then stained with a 2%
alizarin red solution (Sigma, A5533) for 5 min. Cells were then washed three times
Fig. 5 HAUSP regulates osteoblast differentiation by controlling RUNX2 stability. a Ingenuity pathway analysis of proteins that interact with RUNX2-WT
and RUNX2-Tri-A mutant. b–d Human BMSCs expressing control shRNAs or shRNAs targeting the indicated DUBs were cultured under osteogenic
conditions for 7 days and ALP activity was assessed (b). Mineralization (c) and mRNA levels of osteogenic genes (d) in human BMSCs expressing control
(shCtrl) or HAUSP-targeting shRNAs (shHAUSP) were assessed by alizarin red staining at day 18 and by RT-PCR at day 12, respectively. b n= 14; d, n= 4
biologically independent samples. Protein (e) and mRNA (f) levels of RUNX2 in shCtrl or shHAUSP-expressing human BMSCs. f n= 4 biologically
independent samples). g RUNX2 and His-ubiquitin were transfected into HEK293T cells along with different concentrations of HAUSP. 2 days after
transfection, cells were treated with 10 μM MG132 for 6 h, lysed, immunoprecipitated with Ni-NTA agarose, and immunoblotted with anti-RUNX2
antibody. h Cell-free deubiquitination analysis using recombinant HAUSP (rHAUSP) and ubiquitinated Flag-RUNX2 proteins. Flag-RUNX2 and HA-ubiquitin
were co-transfected into HEK293T cells and ubiquitinated Flag-RUNX2 proteins were obtained by immunoprecipitation with anti-Flag-conjugated agarose.
i HEK293T cells were transfected with RUNX2-WT or RUNX2-Tri-A mutant along with HA-HAUSP and treated with 10 μMMG132 for 6 h prior to lysis. HA-
HAUSP immunoprecipitates were immunoblotted with the indicated antibodies. j Cell-free interaction analysis using recombinant RUNX2 (rRUNX2), CK2
(rCK2), and HAUSP (rHAUSP). Recombinant proteins were incubated in the absence or presence of ATP for 30min, immunoprecipitated with anti-RUNX2
antibody and protein G-conjugated agarose, and immunoblotted with the indicated antibodies. k RUNX2-WT or RUNX2-Tri-A mutant was transfected into
HEK293T cells along with different concentrations of HAUSP and immunoblotted with the indicated antibodies. l Schematic diagram depicting a
posttranslational regulation of RUNX2 by the CK2/HAUSP pathway in osteoblasts. Data are representative of three (b–k) independent experiments.
Ordinary one-way ANOVA with Dunnett’s multiple comparisons test (b) and a two-tailed unpaired Student’s t test for comparing two groups (d, f; error
bars, SD of biological replicates).
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with distilled water and examined for the presence of calcium deposits.
Mineralization was quantified by the acetic acid extraction method69.
Osteoclast differentiation. For preparation of bone marrow monocytes, femur
was dissected from 8-week-old mice, and bone marrow cells collected by flushing
were plated overnight in α–MEM with 10% FBS. Non-adherent cells were collected
and seeded on a 100 mm dish with M-CSF (20 ng/ml, R&D systems, 416-ML-010).
After 48 h, adherent cells were plated and cultured in osteoclast differentiation
condition up to 6 days. For osteoclastogenesis, M-CSF (20 ng/ml) and RANKL (10
ng/ml, R&D systems, 462-TEC-010) were added in the growth medium.
RT-PCR, immunoprecipitation, and immunoblotting. To prepare RNA samples
from the mouse limbs, the hindlimbs were dissected and skin/muscle tissues were
removed. The remaining tibias/femurs were chopped and homogenized. For
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extraction RNA from mouse HO models, HO-formed muscle, and HO-formed
achilles tendon were dissected and homogenized mechanically. Total RNAs were
purified using QIAzol (QIAGEN) and cDNA was synthesized using the High-
Capacity cDNA Reverse Transcription Kit from Applied Biosystems. Quantitative
RT-PCR was performed using SYBR® Green PCR Master Mix (Applied Biosys-
tems) with QuantStudio (TM) 6 Flex System (Applied Biosystems). The primers
used for PCR are described in the Supplementary Table 1.
To examine endogenous interaction between RUNX2 and CK2 or USP24, cell
lysates were obtained from mouse COBs and prepared in lysis buffer (50 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 1 mM Na3VO4, 1 mM PMSF, and protease inhibitor cocktail (Sigma)). Cell
lysates were incubated with IgG control or anti-RUNX2 and immunoprecipitated
with protein G-conjugated agarose. For exogenous interaction, HEK293T cells were
transfected with the indicated DNA constructs using the Effectene transfection
reagent (Qiagen) and 48 h later, cell lysates were prepared in lysis buffer. Proteins
from cell lysates were immunoprecipitated with Flag-conjugated (Sigma, A2220) or
HA-conjugated (Santa Cruz, sc-7392 AC) were subjected to SDS-PAGE,
transferred to Immobilon-P membranes (Millipore), immunoblotted with the
indicated antibodies, and developed with ECL (Thermoscientific). Immunoblotting
with antibodies specific to GAPDH or HSP90 was used as a loading control.
Luciferase assay. RUNX2-responsive reporter gene (OG2-Luc) and Renilla luci-
ferase vector (Promega) were transfected into C3H10T1/2 cells or human BMSCs
using the Effectene transfection reagent (Qiagen). After 48 h, dual luciferase assay
was performed according to the manufacturer’s protocol (Promega) and OG2
luciferase activity was normalized to Renilla.
In vitro kinase assay and phospho-mass spectrometry. Two hundred nano-
grams of recombinant CK2 (NEB, P6010) and 300 ng of recombinant RUNX2
(Origene, TP760214) were incubated in kinase buffer (20 mM HEPES, pH 7.5, 20
mM MgCl2, 1 mM EDTA, 2 mM NaF, 2 mM-glycerophosphate, 1 mM DTT, 10
μM ATP) containing 10 μCi of γ32P-ATP (PerkinElmer) for 15 min at 30 °C. The
phosphorylated proteins were visualized by autoradiography.
For phospho-mass spectrometry, 1 μg of recombinant CK2 and RUNX2 were
incubated in kinase buffer containing cold ATP for 30 min at 30 °C, subjected to
SDS-PAGE, and stained with Coomassie blue. Phosphorylated RUNX2 protein at
the band size of 55 kDa was excised and subjected to phospho-mass spectrometry.
Mass spectrometry and IPA. Plasmids expressing Flag-RUNX2-WT (1 μg) or
Flag-RUNX2-Tri-A mutant (2 μg) were transfected into HEK293T cells using the
Effectene transfection reagent. After 48 h, its binding proteins were co-
immunoprecipitated with Flag-conjugated agarose, eluted with excessive amounts
of Flag-peptide, and the eluates were subjected to mass spectrometry. Due to low
expression levels of Flag-RUNX2 (Tri-A), double amounts of the plasmid encoding
Flag-RUNX2 (Tri-A) relative to Flag-RUNX2 (WT) were transfected to
HEK293T cells in order to express equivalent protein levels of Flag-RUNX2.
Expression intensity of peptides obtained from mass spectrometry was applied to
the IPA (Qiagen) to identify proteins that differentially bind to RUNX2-WT vs.
RUNX2-Tri-A mutant. Briefly, expression intensity of peptides from mass spec-
trometry was first uploaded into IPA system for core analysis and then overlaid
with the dataset based on the literature and compiled in the ingenuity pathway
knowledge base. IPA was performed to identify canonical pathways that are most
significant to mass spectrometry outcomes.
Deubiquitination assay. To test the ability of HAUSP to deubiquitinate ubiqui-
tinated RUNX2, plasmids expressing Flag-RUNX2-WT or Flag-RUNX2-Tri-A
mutant were transfected into HEK293T cells along with His-ubiquitin-expressing
plasmid in the absence or presence of HAUSP-expressing plasmid. After 48 h, cells
were treated with 10 μM MG132 (EMD-Millipore, 474790) for 6 h, lysed and
sonicated in denaturation buffer (8 M urea, 50 mM tris pH 8.0, 1.0% triton X-100,
10 mM imidazol, 10 mM β-mercaptoethanol), and immunoprecipitated with Ni-
NTA beads. Immunoprecipitates were subjected to SDS-PAGE and immunoblotted
with anti-RUNX2 antibody.
A cell-free deubiquitination assay was also performed using the purified
ubiquitinated RUNX2 and recombinant HAUSP. Ubiquitinated RUNX2 proteins
were purified from HEK293T cells expressing Flag-RUNX2 and HA-ubiquitin by
immunoprecipitating with Flag-conjugated agarose. These RUNX2 proteins were
subsequently incubated with different amounts of recombinant HAUSP (Boston
Biochem, E-519) in deubiquitination buffer (50 mM Tris-HCl (pH 8.0), 50 mM
NaCl, 1 mM EDTA, 10 mM DTT, 5% glycerol) at 37 °C for 3 h70. Immunoblotting
was performed to measure ubiquitination levels.
RNA sequencing and analysis. Adapters are removed and reads are aligned to
mouse genome GRCm38 by using STAR aligner (ver. 2.3.0e)71 using default
parameters and resulting bam files (mapped reads) were sorted and indexed using
SAMTools72. Gene counts were obtained by HTSeq-Count73 to sorted bam files,
and only unique-mapping reads were used. For dendrogram (heat map) genera-
tion, 3850 total genes were clustered into four groups and the gene sets in these
groups are described in Supplementary Table 2. Genes without any expression
counts in any sample were discarded. The DESeq2 (ver. 1.4.5) in R package74 was
employed to normalize gene count data, and then detect differentially expressed
genes (DEG) between each groups with (FDR < 0.005 and absolute log2 fold change
>1.5). Functional enrichment analysis was performed on DEG with DAVID (ver.
6.7)75 and biological process GO terms with enrichment p < 0.05 were selected as
overrepresented functions. Summary statistics of the fold change analysis in each of
the GO categories is described in Supplementary Table 3.
Collection of CM from WT and Csnk2b KO COBs. CM from primary WT and
Csnk2b-deficient COBs was collected at day 0 (undifferentiated COBs) and day 7
(differentiated osteoblasts) after osteogenic induction. CM for each group was
collected after three washes with PBS to remove serum and incubated with serum
free α-MEM for 24 h. After incubation, each CM sample was collected and filtered
with 0.45 μm syringe filter to remove cellular debris.
Endothelial cell culture and functional assays. Mouse bone marrow-derived
Endothelial progenitor outgrowth cells (EPOCs) were purchased from BioChain
(Z7030031) and maintained in growth medium (BioChain, Z7030035). Cell
migration was performed using chemotaxis chamber (Biovision, K906) as manu-
facturer’s instructions. Briefly, basal medium or CM or FGF-2 (R&D systems,
3139-FB-025) was placed in the bottom wells of the chamber and the upper
chamber was loaded with 10,000 cells/well. After incubation for 6 h at 37 °C, the
migrated cells were analyzed and quantified.
For tube formation, EPOCs (100,000 cells/well) were plated into 48-well plates
coated with growth factor-reduced matrigel (Corning, 354230) and incubated for
24 h at 37 °C in indicated conditions. Total tube length was measured by counting a
random field per well with microscopy (5–7 wells per each group).
Statistics and reproducibility. All experiments were carried out at least two or
three times, for IHC, immunofluorescence staining, histological staining, skeletal
Fig. 6 HAUSP is required for maturation of osteoprogenitors in vitro and in vivo. a–e COBs isolated from P5 Hauspfl/fl pups were infected with
lentiviruses expressing vector (WT) or Cre recombinase (Hausp KO) and cultured under osteogenic conditions. RT-PCR analysis to measure mRNA levels
of Hausp and osteogenic genes (a) and ALP activity (b, left) and staining (b, right) were performed 7 days after the culture. Mineralization was assessed by
alizarin red staining 16 days after the culture (c). Protein (d) and mRNA (e) levels of RUNX2 were assessed in these COBs. Scale bar, 100 μm (b). a, e n=
4; b, c n= 9. f shCtrl or shHausp-expressing C3H10T1/2 cells were transfected with OG2-luc and Renilla in the presence or absence of RUNX2
overexpression. Two days after transfection, OG2-luc activity was measured and normalized to Renilla. (n= 6 biologically independent samples). Hausp-
sufficient or -deficient COBs were infected with lentiviruses expressing vector or RUNX2, cultured under osteogenic conditions for 7 days, and ALP activity
(g) and mRNA levels of Bglap2 (h) were assessed. g n= 6; h n= 4 biologically independent samples). i Hausp mRNA levels in P0 Hauspfl/fl, Osx-Cre, and
Hausp+/Osx calvaria. (n= 4). j, l,mMicroCT analysis shows 3D-reconstruction of calvaria (j) and femurs (l) from 2-month-old Hauspfl/fl, Osx-Cre and Hausp
+/Osx male mice. Quantification of femoral bone mass is displayed (m). The arrows indicate hypomineralization areas. Scale bars, 2 mm (j); 500 μm (l). m
n= 10 (Hauspfl/fl), 5 (Osx-Cre) or 10 (Hausp+/Osx). k Alizarin red/alcian blue staining of skeletal preparations of clavicles obtained from 2-month-old
Hauspfl/fl, Osx-Cre and Hausp+/Osx male mice. Scale bar, 2 mm. n H&E-stained longitudinal sections of femurs from 2-month-old Osx-Cre and Hausp+/Osx
male mice. Scale bar, 50 μm. Alizarin red/alcian blue staining of skeletal preparations of calvaria (top) and clavicles (bottom) from P10 Osx-Cre, Csnk2b
+/Osx, Hausp+/Osx, and Csnk2b+/Osx;Hausp+/Osx mice (o) and Osx-Cre, Runx2+/Osx, Runx2+/Osx;Csnk2b+/Osx, and Runx2+/Osx;Hausp+/Osx mice (p). Scale
bars, 2 mm (o, p). Data are representative of three (a–l, n–p) independent experiments or are pooled from two experiments (m). A two-tailed unpaired
Student’s t test for comparing two groups (a–c, e–i, m; error bars, SD of biological replicates).
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preparation, flow cytometry, and immunoblotting, representative images are
shown. All data are shown as the mean ± Standard Deviation (SD). We first per-
formed the Shapiro–Wilk normality test for checking normal distributions of the
groups. If normality tests passed, two-tailed, unpaired Student’s t test and if nor-
mality tests failed, and Mann–Whitney tests were used for the comparisons
between two groups. For the comparisons of three or four groups, we used one-way
ANOVA if normality tests passed, followed by Tukey’s multiple comparison test
for all pairs of groups. The GraphPad PRISM software (ver.8.3.0, La Jolla, CA) was
used for statistical analysis. P < 0.05 was considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Data supporting the findings of this manuscript are available from the corresponding
author upon reasonable request.
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